CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery

BACKGROUND: There is no consensus regarding the management of ovarian cancer patients, who have shown complete clinical response (CCR) to primary therapy and have rising cancer antigen CA-125 levels but have no symptoms of recurrent disease. The present study aims to determine whether follow-up CA-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fang, Ye, Yanfen, Xu, Xia, Zhou, Xuehui, Wang, Jinhua, Chen, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576242/
https://www.ncbi.nlm.nih.gov/pubmed/23402322
http://dx.doi.org/10.1186/1757-2215-6-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576242/
https://www.ncbi.nlm.nih.gov/pubmed/23402322
http://dx.doi.org/10.1186/1757-2215-6-14

Ejemplares similares